Dean Li, president of Merck Research Laboratories, said in the statement that the drug had potential to provide additional cardiometabolic benefits beyond weight reduction. In the release, Merck didnt specify which diseases it planned to test the drug on first
GLP-1 therapy starts at a low dose and titrates gradually to minimize gastrointestinal side effects the most common being nausea, particularly during dose increases
Our concierge nurses bring IV hydration and vitamin infusions to your home, office, hotel, gym, or event
Patients with type 2 diabetes often struggle with weight management, and GLP1 receptor agonists have emerged as dual-purpose agents
LillyDirect and Walmart Pharmacy Launch First Retail Pick-Up Option With Direct-to-Consumer Pricing for Zepbound
3 How semaglutide lowers heart disease risk The SELECT trial followed 17,604 adults with established cardiovascular disease and a BMI of 27 or above, none of whom had diabetes